Harder targets, stronger starts.
Advanced Lab antibody discovery and development
#1 ranking CRO*
Deep wet lab expertise. Your strategic scientific thought partner to help uncover diverse candidates with strong potential.
* ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Function first, from the start.
MindWalk provides end-to-end antibody discovery services through a Function-First approach that brings functional screening, developability, and risk considerations earlier in discovery. Clients work 1:1 with scientific and technology experts to shape a customized program around their target and goals. We combine target-informed immunization, rigorous wet lab analysis, AI-enabled insights, and deep antibody expertise to generate diverse, phenotypically relevant antibody panels. This integrated approach supports more informed candidate selection, lead optimization, and downstream development.
Impact
35+ years
Decades of experience, high client retention
Discovery
>98% success*
Using leading B cell Select® technology for advanced antibody discovery
*“Success” refers to meeting predefined discovery criteria, not clinical or therapeutic outcomes. Results may vary.
Track record
20+ antibodies
20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.
Programs
3,000+ programs
Completed partner programs; used by 19 of the top 20 global pharma.
Transforming workflows
Comprehensive continuum
Front-loading discovery brings functional screening, developability, and risk forward from the first immunization. As a recognized global wet lab leader, we pair that with AI-enabled analysis from the earliest stage to support evidence-based candidate evaluation as programs move into development.
Workflows designed to support candidate progression
Early-stage insights bring biological context forward, helping teams identify promising antibodies and make more informed development decisions.
Used by teams across 19 of the top 20 global pharma companies, next-generation biotechs, and leading research institutions
3,000+ completed partner programs
across therapeutic, diagnostic and anti-idiotypic antibody discovery
Advanced lab. Thirty-five years of it.
Led by scientists, our lab combines depth, precision, and versatility to advance antibody discovery, with LensAI™ analysis alongside the bench to evaluate every candidate.
Wet lab antibody discovery and development
As a global leader in antibody discovery, we deliver state-of-the-art research that supports programs from exploration through downstream development. Our platforms are recognized for diversity and reproducibility, helping teams move promising candidates forward.
Antibody discovery with LensAI™ analysis
B cell Select®
Identify top antibodies early with function-first screening of target-enriched B cells. Multi-species versatility, high efficiency and exceptional hit-rate, native pair identification and LensAI™ analysis make it especially powerful for challenging programs. With a demonstrated >98% success rate, B cell Select® has contributed to multiple publicly disclosed client candidates now in the clinic.
Antibody discovery with LensAI™ analysis
Hybridoma
Discover top antibodies in just two weeks with MindWalk’s single-step Hybridoma platform, leveraging semi-solid media and direct colony picking. Function-first screening, target-agnostic design, and the ability to accommodate challenging functional assays support the rapid identification of high-value clones across all targets.
Antibody discovery with LensAI™ analysis
Yeast Display
Yeast display is a highly effective platform for screening antibody libraries from immune sources as well as for engineering of pre-existing clones. The fidelity of expression in the eukaryotic system combined with the affinity selection by FACS enables rapid enrichment and selection of clones with the most desirable properties.
Antibody Development with LensAI
Lead Characterization
Newly discovered antibody hits are systematically analyzed across structural, functional, and developability dimensions—including structural, functional, liability, immunogenicity, and paratope profiles—using integrated computational and experimental approaches to identify the most clinic-ready clones early in discovery.
Antibody Development with LensAI
Lead Optimization
Powered by the LensAI platform and HYFT® technology, our lead optimization integrates AI-guided rational design with wet-lab validation and simultaneous multi-feature analysis. The result is designed to deliver faster, data-driven refinement that minimizes trial-and-error, reduces early risk, and produces optimized leads with stronger performance and lower late-stage attrition.
Antibody Development with LensAI
Candidate Selection
MindWalk’s AI platform delivers smarter and faster discovery and development processes to achieve candidate selection with the highest confidence.
See how B cell Select®, hybridoma, and yeast display discovery work, and where LensAI™ analysis fits. Learn more
Emerging discovery modalities
Our discovery workflows span peptides, vaccines, and cell therapies, with the lab providing the experimental depth to validate every insight.
AI inside the lab work
LensAI™ Data + Insights Foundation
Bring more biological evidence into target identification, validation, and early discovery decisions.
LensAI™ Exploration Layer
Reveal hidden relationships in discovery to guide hit selection and prioritization and surface potential risk earlier.
LensAI™ Engineering + Design Engine
Surface potential risk, evaluate design tradeoffs, and prioritize changes through engineering and optimization.
Collaboration that drives discovery
Each program is unique. We create custom solutions as part of your team, combining deep scientific expertise and technical insight with open collaboration. Many clients describe MindWalk as their thought partner—driven to advance results to the clinic.
Integrated biologics discovery and development
Anti-drug and anti-idiotype antibodies
Strong performance, high reliability, high client retention
Where our research makes a broad impact
Oncology + Infectious Disease + Neurodegeneration + Metabolic Disease + Rare Disease + Inflammation
Tell us about your target.
A scientist, not a sales rep, replies within two business days.
Let's expand what's possible for human health
Case Studies
See validated insights that redefine workflows and advance discovery.
Scientific Posters
Discover how MindWalk powers smarter paths from concept to clinic.
Blogs
Explore latest ideas reshaping the future of discovery.
Let’s shape the future
One BioIntelligence Ecosystem, explore partnership opportunities
Upcoming Events
Join us for ideas, conversations, and collaboration.
BioTechX Europe 2026
Basel, Switzerland
Oct 6-8, 2026
Festival of Biologics 2026
Basel, Switzerland
Oct 13-15, 2026
AI-Driven Drug Discovery Summit 2026
Boston USA
Oct 27-29, 2026
PEGS Europe 2026
Lisbon, Portugal
Nov 17-19, 2026
Antibody Engineering & Therapeutics 2026
San Diego USA
Dec 13-16, 2026